Jazz Pharmaceuticals Announces First Patient Enrolled In IMforte Phase 3 Trial Evaluating Zepzelca In Combination With A PD-L1 Inhibitor In Small Cell Lung Cancer

by | Nov 30, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.